BRIEF-Entero Therapeutics Says Immunogenx Received Notice Of Default, Demand For Payment Relating To Credit Agreement

Reuters11-28

BRIEF-Entero <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Says Immunogenx Received Notice Of Default, Demand For Payment Relating To Credit Agreement

Nov 27 (Reuters) - Entero Therapeutics Inc ENTO.O:

ENTERO THERAPEUTICS: ON NOV 21, IMMUNOGENX RECEIVED NOTICE OF DEFAULT, DEMAND FOR PAYMENT RELATING TO CREDIT AGREEMENT, DATED AS OF OCT 3, 2022
ENTERO THERAPEUTICS : NOTICE INFORMED IMMUNOGENX THAT ONE OR MORE EVENTS OF DEFAULT UNDER CREDIT AGREEMENT WERE EXISTING AND CONTINUING
ENTERO THERAPEUTICS INC: ACCELERATION OR REDUCTION OF CASH OUTFLOWS AND DEBT OBLIGATIONS CAN SIGNIFICANTLY IMPACT OUR ABILITY TO MAINTAIN OPERATIONS
ENTERO THERAPEUTICS INC: HAVE REDUCED HEADCOUNT AND PAUSED DEVELOPMENT ACTIVITIES
ENTERO THERAPEUTICS INC: EXPLORING STRATEGIC ALTERNATIVES FOR PURPOSE OF MAXIMIZING VALUE OF ALL OF OUR STAKEHOLDERS
ENTERO THERAPEUTICS INC: EXPECT TO CONTINUE TO, EXPLORE VARIOUS POTENTIAL STRATEGIES AVAILABLE TO CO

Source text: [ID:n0001104659-24-123742]

Further company coverage: ENTO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486818183?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-28 07:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486818183","market":"us","top_or_hot":-1,"title":"BRIEF-Entero Therapeutics Says Immunogenx Received Notice Of Default, Demand For Payment Relating To Credit Agreement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Entero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Says Immunogenx Received Notice Of Default, Demand For Payment Relating To Credit Agreement</title></head><body><p><span>Nov 27 (Reuters)</span><span> - </span>Entero Therapeutics Inc <span>ENTO.O</span>:</p><ul><li><p>ENTERO THERAPEUTICS: ON NOV 21, IMMUNOGENX RECEIVED NOTICE OF DEFAULT, DEMAND FOR PAYMENT RELATING TO CREDIT AGREEMENT, DATED AS OF OCT 3, 2022</p></li><li><p>ENTERO THERAPEUTICS : NOTICE INFORMED IMMUNOGENX THAT ONE OR MORE EVENTS OF DEFAULT UNDER CREDIT AGREEMENT WERE EXISTING AND CONTINUING</p></li><li><p>ENTERO THERAPEUTICS INC: ACCELERATION OR REDUCTION OF CASH OUTFLOWS AND DEBT OBLIGATIONS CAN SIGNIFICANTLY IMPACT OUR ABILITY TO MAINTAIN OPERATIONS</p></li><li><p>ENTERO THERAPEUTICS INC: HAVE REDUCED HEADCOUNT AND PAUSED DEVELOPMENT ACTIVITIES</p></li><li><p>ENTERO THERAPEUTICS INC: EXPLORING STRATEGIC ALTERNATIVES FOR PURPOSE OF MAXIMIZING VALUE OF ALL OF OUR STAKEHOLDERS</p></li><li><p>ENTERO THERAPEUTICS INC: EXPECT TO CONTINUE TO, EXPLORE VARIOUS POTENTIAL STRATEGIES AVAILABLE TO CO</p></li></ul><p>Source text: [ID:n0001104659-24-123742]</p><p>Further company coverage: <span>ENTO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Entero Therapeutics Says Immunogenx Received Notice Of Default, Demand For Payment Relating To Credit Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Entero Therapeutics Says Immunogenx Received Notice Of Default, Demand For Payment Relating To Credit Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-28 07:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nFWN3MY1FE:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Entero Therapeutics Says Immunogenx Received Notice Of Default, Demand For Payment Relating To Credit AgreementNov 27 (Reuters) - Entero Therapeutics Inc ENTO.O:ENTERO THERAPEUTICS: ON NOV 21, ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nFWN3MY1FE:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENTO","symbol_name":"Entero Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nFWN3MY1FE:1","article_id":"2486818183","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486818183","pubTimestamp":1732749873,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Entero Therapeutics Says Immunogenx Received Notice Of Default, Demand For Payment Relating To Credit AgreementNov 27  - Entero Therapeutics Inc ENTO.O:ENTERO THERAPEUTICS: ON NOV 21, IMMUNOGENX RECEIVED NOTICE OF DEFAULT, DEMAND FOR PAYMENT RELATING TO CREDIT AGREEMENT, DATED AS OF OCT 3, 2022ENTERO THERAPEUTICS : NOTICE INFORMED IMMUNOGENX THAT ONE OR MORE EVENTS OF DEFAULT UNDER CREDIT AGREEMENT WERE EXISTING AND CONTINUINGENTERO THERAPEUTICS INC: ACCELERATION OR REDUCTION OF CASH OUTFLOWS AND DEBT OBLIGATIONS CAN SIGNIFICANTLY IMPACT OUR ABILITY TO MAINTAIN OPERATIONSENTERO THERAPEUTICS INC: HAVE REDUCED HEADCOUNT AND PAUSED DEVELOPMENT ACTIVITIESENTERO THERAPEUTICS INC: EXPLORING STRATEGIC ALTERNATIVES FOR PURPOSE OF MAXIMIZING VALUE OF ALL OF OUR STAKEHOLDERSENTERO THERAPEUTICS INC: EXPECT TO CONTINUE TO, EXPLORE VARIOUS POTENTIAL STRATEGIES AVAILABLE TO COSource text: [ID:n0001104659-24-123742]Further company coverage: ENTO.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ENTO":"Entero Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"简介-Entero Therapeutics表示Immunogenx收到违约通知，要求与信贷协议相关的付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENTO":0.9},"content_text":"BRIEF-Entero Therapeutics Says Immunogenx Received Notice Of Default, Demand For Payment Relating To Credit AgreementNov 27 (Reuters) - Entero Therapeutics Inc ENTO.O:ENTERO THERAPEUTICS: ON NOV 21, IMMUNOGENX RECEIVED NOTICE OF DEFAULT, DEMAND FOR PAYMENT RELATING TO CREDIT AGREEMENT, DATED AS OF OCT 3, 2022ENTERO THERAPEUTICS : NOTICE INFORMED IMMUNOGENX THAT ONE OR MORE EVENTS OF DEFAULT UNDER CREDIT AGREEMENT WERE EXISTING AND CONTINUINGENTERO THERAPEUTICS INC: ACCELERATION OR REDUCTION OF CASH OUTFLOWS AND DEBT OBLIGATIONS CAN SIGNIFICANTLY IMPACT OUR ABILITY TO MAINTAIN OPERATIONSENTERO THERAPEUTICS INC: HAVE REDUCED HEADCOUNT AND PAUSED DEVELOPMENT ACTIVITIESENTERO THERAPEUTICS INC: EXPLORING STRATEGIC ALTERNATIVES FOR PURPOSE OF MAXIMIZING VALUE OF ALL OF OUR STAKEHOLDERSENTERO THERAPEUTICS INC: EXPECT TO CONTINUE TO, EXPLORE VARIOUS POTENTIAL STRATEGIES AVAILABLE TO COSource text: [ID:n0001104659-24-123742]Further company coverage: ENTO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486818183"}